214.25 USD
-3.75 (-1.72%)
Taking everything into account, KRYS scores 6 out of 10 in our fundamental rating. KRYS was compared to 534 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. KRYS is valued quite cheap, while showing a decent growth score. This is a good combination! This makes KRYS very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year KRYS was profitable.
KRYS had a positive operating cash flow in the past year.
In multiple years KRYS reported negative net income over the last 5 years.
In the past 5 years KRYS reported 4 times negative operating cash flow.
1.2 Ratios
KRYS has a Return On Assets of 16.04%. This is amongst the best in the industry. KRYS outperforms 95.69% of its industry peers.
KRYS has a Return On Equity of 17.48%. This is amongst the best in the industry. KRYS outperforms 95.32% of its industry peers.
The Return On Invested Capital of KRYS (12.28%) is better than 94.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROIC | 12.28% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KRYS has a better Profit Margin (53.30%) than 98.69% of its industry peers.
With an excellent Operating Margin value of 42.40%, KRYS belongs to the best of the industry, outperforming 99.25% of the companies in the same industry.
Looking at the Gross Margin, with a value of 94.26%, KRYS belongs to the top of the industry, outperforming 93.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so KRYS is still creating some value.
Compared to 1 year ago, KRYS has more shares outstanding
Compared to 5 years ago, KRYS has more shares outstanding
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
KRYS has an Altman-Z score of 38.61. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
KRYS's Altman-Z score of 38.61 is amongst the best of the industry. KRYS outperforms 95.69% of its industry peers.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 38.61 |
ROIC/WACC1.42
WACC8.66%
2.3 Liquidity
KRYS has a Current Ratio of 10.14. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS has a better Current ratio (10.14) than 81.09% of its industry peers.
KRYS has a Quick Ratio of 9.73. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS's Quick ratio of 9.73 is amongst the best of the industry. KRYS outperforms 80.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 |
3. Growth
3.1 Past
KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 276.84%, which is quite impressive.
Looking at the last year, KRYS shows a very strong growth in Revenue. The Revenue has grown by 54.51%.
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
3.2 Future
KRYS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.10% yearly.
KRYS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.67% yearly.
EPS Next Y70.36%
EPS Next 2Y62.16%
EPS Next 3Y55.07%
EPS Next 5Y58.1%
Revenue Next Year32.01%
Revenue Next 2Y39.8%
Revenue Next 3Y41.2%
Revenue Next 5Y31.67%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 32.12, KRYS can be considered very expensive at the moment.
Based on the Price/Earnings ratio, KRYS is valued cheaper than 92.13% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.31. KRYS is valued slightly more expensive when compared to this.
KRYS is valuated quite expensively with a Price/Forward Earnings ratio of 27.25.
Compared to the rest of the industry, the Price/Forward Earnings ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 91.76% of the companies listed in the same industry.
KRYS is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.12 | ||
| Fwd PE | 27.25 |
4.2 Price Multiples
KRYS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. KRYS is cheaper than 91.95% of the companies in the same industry.
92.32% of the companies in the same industry are more expensive than KRYS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.52 | ||
| EV/EBITDA | 32.18 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KRYS has a very decent profitability rating, which may justify a higher PE ratio.
KRYS's earnings are expected to grow with 55.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.46
PEG (5Y)N/A
EPS Next 2Y62.16%
EPS Next 3Y55.07%
5. Dividend
5.1 Amount
No dividends for KRYS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KRYS (12/1/2025, 12:06:05 PM)
214.25
-3.75 (-1.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.05%
Inst Owner Change2.8%
Ins Owners11.86%
Ins Owner Change-1.19%
Market Cap6.21B
Revenue(TTM)373.16M
Net Income(TTM)198.91M
Analysts84.44
Price Target226.9 (5.9%)
Short Float %11.62%
Short Ratio8.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.19%
Min EPS beat(2)12.14%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)41.54%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)30.53%
EPS beat(12)5
Avg EPS beat(12)2.39%
EPS beat(16)7
Avg EPS beat(16)0.53%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.42%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)4
Avg Revenue beat(8)4.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.08%
PT rev (3m)7.94%
EPS NQ rev (1m)1.24%
EPS NQ rev (3m)-0.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.12 | ||
| Fwd PE | 27.25 | ||
| P/S | 16.65 | ||
| P/FCF | 37.52 | ||
| P/OCF | 35.26 | ||
| P/B | 5.46 | ||
| P/tB | 5.46 | ||
| EV/EBITDA | 32.18 |
EPS(TTM)6.67
EY3.11%
EPS(NY)7.86
Fwd EY3.67%
FCF(TTM)5.71
FCFY2.67%
OCF(TTM)6.08
OCFY2.84%
SpS12.87
BVpS39.24
TBVpS39.24
PEG (NY)0.46
PEG (5Y)N/A
Graham Number76.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROCE | 13.77% | ||
| ROIC | 12.28% | ||
| ROICexc | 33.76% | ||
| ROICexgc | 33.76% | ||
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% | ||
| FCFM | 44.37% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 213.54% | ||
| Cap/Sales | 2.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 107.96% | ||
| Profit Quality | 83.25% | ||
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 | ||
| Altman-Z | 38.61 |
F-Score7
WACC8.66%
ROIC/WACC1.42
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
EPS Next Y70.36%
EPS Next 2Y62.16%
EPS Next 3Y55.07%
EPS Next 5Y58.1%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
Revenue Next Year32.01%
Revenue Next 2Y39.8%
Revenue Next 3Y41.2%
Revenue Next 5Y31.67%
EBIT growth 1Y143.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.9%
EBIT Next 3Y73.68%
EBIT Next 5YN/A
FCF growth 1Y239.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.59%
OCF growth 3YN/A
OCF growth 5YN/A
KRYSTAL BIOTECH INC / KRYS FAQ
Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?
ChartMill assigns a fundamental rating of 6 / 10 to KRYS.
What is the valuation status of KRYSTAL BIOTECH INC (KRYS) stock?
ChartMill assigns a valuation rating of 7 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Undervalued.
What is the profitability of KRYS stock?
KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.
What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?
The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 9 / 10.